TrialClinical pharmacokinetics2003

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Karin Wåhlander et al.PubMed ↗Publisher ↗

No numbers read from the abstract.